Literature DB >> 34386162

Gender disparity in the prescription of secondary prevention medications in a Malaysian primary care clinic.

Noorhida Baharudin1, Ahmad Muslim Ahmad Roslan2, Mohamed Syarif Mohamed Yassin3, Anis Safura Ramli4,5, Aiza Nur Izdihar Zainal Abidin6, Nurul Hidayatullaila Sahar7, Nor Shazatul Salwana Din8, Izyana Syazlin Ibrahim9, Siti Nur Hidayah Abd Rahim10, Nur Athirah Rosli11.   

Abstract

INTRODUCTION: Cardiovascular disease is the leading cause of death worldwide. Despite the proven benefit of secondary prevention medications (SPMs), their utilisation remains suboptimal in many countries. This study aimed to assess the use of SPMs in a Malaysian primary care clinic and factors associated with it.
METHODS: A retrospective review of electronic medical records was conducted to assess the prescription of SPMs among patients with coronary artery disease who attended the clinic between 1st January 2018 and 31st December 2018. Prescriptions of SPMs were documented in numbers and percentages. Multiple logistic regressions were used to analyse factors associated with the prescription of SPMs.
RESULTS: Of the 662 patients included in the study, 99.1% were prescribed statins, 97% antiplatelets, 81.7% angiotensin-converting enzyme (ACE)-inhibitors or angiotensin II receptor blockers (ARBs), and 78.7% beta-blockers. Male patients were more likely to be prescribed statins (OR = 8.584, 95% CI: 1.431 - 51.510) and antiplatelets (OR = 6.818, 95% CI: 2.294 - 20.257). Another significant factor for antiplatelets prescription was having diabetes (OR = 3.318, 95% CI: 1.148 - 9.590). Having hypertension was associated with ACE-inhibitors or ARBs prescription (OR = 4.008, 95% CI: 2.522 - 6.370).
CONCLUSION: Although the majority of patients received SPMs, there were significant disparities for some SPMs prescriptions among female patients. As these medications are widely available in the Malaysian primary care setting, steps should be taken to ensure that these medications are prescribed equally for all eligible patients. © Academy of Family Physicians of Malaysia.

Entities:  

Keywords:  Malaysia; Secondary prevention medications; gender disparity; primary care

Year:  2021        PMID: 34386162      PMCID: PMC8346747          DOI: 10.51866/oa1080

Source DB:  PubMed          Journal:  Malays Fam Physician        ISSN: 1985-2274


  21 in total

1.  Interventions to Improve Medication Adherence: A Review.

Authors:  Vinay Kini; P Michael Ho
Journal:  JAMA       Date:  2018-12-18       Impact factor: 56.272

Review 2.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.

Authors:  Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko
Journal:  J Am Coll Cardiol       Date:  2006-02-07       Impact factor: 24.094

3.  Auditing secondary prevention of ischaemic heart disease in rural areas of Spain: an opportunity for improvement.

Authors:  José M Turón; Julián Librero; Gabriel J Diaz; Juan J García; Carme Beltral; Francisco Abal
Journal:  Eur J Gen Pract       Date:  2006       Impact factor: 1.904

4.  Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014.

Authors:  Robert S Rosenson; Michael E Farkouh; Matthew Mefford; Vera Bittner; Todd M Brown; Ben Taylor; Keri L Monda; Hong Zhao; Yuling Dai; Paul Muntner
Journal:  J Am Coll Cardiol       Date:  2017-06-06       Impact factor: 24.094

5.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

6.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

7.  Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.

Authors:  Michelle F Magee; Jacqueline E Tamis-Holland; Jiang Lu; Vera A Bittner; Maria Mori Brooks; Neuza Lopes; Alice K Jacobs
Journal:  Int J Endocrinol       Date:  2015-03-19       Impact factor: 3.257

8.  Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus.

Authors:  Casper H Jørgensen; Gunnar H Gislason; Ole Ahlehoff; Charlotte Andersson; Christian Torp-Pedersen; Peter R Hansen
Journal:  BMC Cardiovasc Disord       Date:  2014-01-09       Impact factor: 2.298

9.  Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.

Authors:  Tian-Tian Ma; Ian C K Wong; Kenneth K C Man; Yang Chen; Thomas Crake; Muhiddin A Ozkor; Ling-Qing Ding; Zi-Xuan Wang; Lin Zhang; Li Wei
Journal:  PLoS One       Date:  2019-01-18       Impact factor: 3.240

10.  Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people.

Authors:  Yiping Chen; Liming Li; Qiuli Zhang; Robert Clarke; Junshi Chen; Yu Guo; Zheng Bian; Xianhai Pan; Richard Peto; Ran Tao; Kunxiang Shi; Rory Collins; Liangcai Ma; Huarong Sun; Zhengming Chen
Journal:  Int J Cardiol       Date:  2013-12-28       Impact factor: 4.164

View more
  1 in total

1.  Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study.

Authors:  Noorhida Baharudin; Mohamed-Syarif Mohamed-Yassin; Aqil Mohammad Daher; Anis Safura Ramli; Nor-Ashikin Mohamed Noor Khan; Suraya Abdul-Razak
Journal:  BMC Public Health       Date:  2022-02-04       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.